Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30–40% of patients fail to respond or relapse after treatment. Hence, to identify new molecular alterations that allow for identification of patients unlikely to respond to AZA could impact the u...

Full description

Saved in:
Bibliographic Details
Main Authors: Valencia, A, Masala, E, Rossi, A, Martino, A, Sanna, A, Buchi, F, Canzian, F, Cilloni, D, Gaidano, V, Voso, M T, Kosmider, O, Fontenay, M, Gozzini, A, Bosi, A, Santini, V
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2014
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3948159/
https://ncbi.nlm.nih.gov/pubmed/24192812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.330
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items